PMID- 36319858
OWN - NLM
STAT- MEDLINE
DCOM- 20230112
LR  - 20240415
IS  - 1432-1912 (Electronic)
IS  - 0028-1298 (Print)
IS  - 0028-1298 (Linking)
VI  - 396
IP  - 2
DP  - 2023 Feb
TI  - Cardiac effects of ephedrine, norephedrine, mescaline, and 
      3,4-methylenedioxymethamphetamine (MDMA) in mouse and human atrial preparations.
PG  - 275-287
LID - 10.1007/s00210-022-02315-2 [doi]
AB  - The use of recreational drugs like ephedrine, norephedrine, 
      3,4-methylenedioxymethamphetamine (MDMA), and mescaline can lead to intoxication 
      and, at worst, to death. One reason for a fatal course of intoxication with these 
      drugs might lie in cardiac arrhythmias. To the best of our knowledge, their 
      inotropic effects have not yet been studied in isolated human cardiac 
      preparations. Therefore, we measured inotropic effects of the hallucinogenic 
      drugs ephedrine, norephedrine, mescaline, and MDMA in isolated mouse left atrial 
      (mLA) and right atrial (mRA) preparations as well as in human right atrial (hRA) 
      preparations obtained during cardiac surgery. Under these experimental 
      conditions, ephedrine, norephedrine, and MDMA increased force of contraction 
      (mLA, hRA) and beating rate (mRA) in a time- and concentration-dependent way, 
      starting at 1-3 microM but these drugs were less effective than isoprenaline. 
      Mescaline alone or in the presence of phosphodiesterase inhibitors did not 
      increase force in mLA or hRA. The positive inotropic effects of ephedrine, 
      norephedrine, or MDMA were accompanied by increases in the rate of tension and 
      relaxation and by shortening of time of relaxation and, moreover, by an augmented 
      phosphorylation state of the inhibitory subunit of troponin in hRA. All effects 
      were greatly attenuated by cocaine (10 microM) or propranolol (10 microM) treatment. In 
      summary, the hallucinogenic drugs ephedrine, norephedrine, and MDMA, but not 
      mescaline, increased force of contraction and increased protein phosphorylation 
      presumably, in part, by a release of noradrenaline in isolated human atrial 
      preparations and thus can be regarded as indirect sympathomimetic drugs in the 
      human atrium.
CI  - (c) 2022. The Author(s).
FAU - Neumann, Joachim
AU  - Neumann J
AD  - Institute for Pharmacology and Toxicology, Medical Faculty, Martin Luther 
      University Halle-Wittenberg, Magdeburger Str. 4, D-06097, Halle, Germany.
FAU - Azatsian, Karyna
AU  - Azatsian K
AD  - Institute for Pharmacology and Toxicology, Medical Faculty, Martin Luther 
      University Halle-Wittenberg, Magdeburger Str. 4, D-06097, Halle, Germany.
FAU - Hohm, Christian
AU  - Hohm C
AD  - Institute for Pharmacology and Toxicology, Medical Faculty, Martin Luther 
      University Halle-Wittenberg, Magdeburger Str. 4, D-06097, Halle, Germany.
FAU - Hofmann, Britt
AU  - Hofmann B
AD  - Department of Cardiac Surgery, Mid-German Heart Center, University Hospital 
      Halle, D-06097, Halle, Germany.
FAU - Gergs, Ulrich
AU  - Gergs U
AD  - Institute for Pharmacology and Toxicology, Medical Faculty, Martin Luther 
      University Halle-Wittenberg, Magdeburger Str. 4, D-06097, Halle, Germany. 
      ulrich.gergs@medizin.uni-halle.de.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20221101
PL  - Germany
TA  - Naunyn Schmiedebergs Arch Pharmacol
JT  - Naunyn-Schmiedeberg's archives of pharmacology
JID - 0326264
RN  - KE1SEN21RM (N-Methyl-3,4-methylenedioxyamphetamine)
RN  - RHO99102VC (Mescaline)
RN  - 0 (Hallucinogens)
RN  - GN83C131XS (Ephedrine)
RN  - 33RU150WUN (Phenylpropanolamine)
SB  - IM
MH  - Humans
MH  - Mice
MH  - Animals
MH  - *N-Methyl-3,4-methylenedioxyamphetamine/toxicity
MH  - Mescaline/pharmacology
MH  - *Hallucinogens/toxicity
MH  - Ephedrine/pharmacology
MH  - Phenylpropanolamine/pharmacology
MH  - *Atrial Fibrillation
MH  - Heart Atria
MH  - Myocardial Contraction
PMC - PMC9831963
OTO - NOTNLM
OT  - 3,4-Methylenedioxymethamphetamine (MDMA)
OT  - Chronotropy
OT  - Ephedrine
OT  - Human atrium
OT  - Inotropy
OT  - Mescaline
OT  - Norephedrine
OT  - Troponin inhibitor
COIS- The authors declare no competing interests.
EDAT- 2022/11/03 06:00
MHDA- 2023/01/13 06:00
PMCR- 2022/11/01
CRDT- 2022/11/02 00:38
PHST- 2022/08/22 00:00 [received]
PHST- 2022/10/20 00:00 [accepted]
PHST- 2022/11/03 06:00 [pubmed]
PHST- 2023/01/13 06:00 [medline]
PHST- 2022/11/02 00:38 [entrez]
PHST- 2022/11/01 00:00 [pmc-release]
AID - 10.1007/s00210-022-02315-2 [pii]
AID - 2315 [pii]
AID - 10.1007/s00210-022-02315-2 [doi]
PST - ppublish
SO  - Naunyn Schmiedebergs Arch Pharmacol. 2023 Feb;396(2):275-287. doi: 
      10.1007/s00210-022-02315-2. Epub 2022 Nov 1.